Cancer Hormone Prostate Refractory and Chemotherapy for Hormonal Refractory Prostate Cancer

Diseases come in all shapes and sizes, and cancer of the prostate is not to be left out of that circuit. Even though this disease is mostly a carcinoma that affects the elderly, it is also known to affect men younger than the age of 40 in a few rear cases. Likewise, the disease is typically a slow-growing, slow-progressing melanoma that might not inflict you with symptoms before something else hits you and takes you to the other side, even though it could actually be there; there are however instances in which this cancerous tumor can be very aggressive and metastatic.

Hormonal refractory prostate cancer is easily one of the worst manifestations of the disease, a condition at which many physicians believe that palliative care might simply be the best they can offer the patient. It signals a stage of progression and metastasis of the disease such that hormone treatments no longer work to control or even slow the growth of the disease. Palliative care is often considered for advanced stage prostate cancer with a focus more on extending the life of the patient, and relieving the symptoms of the patient’s suffering in the instance of metastatic disease.

Even then, the patient does have the right to insist on treatment, in spite of the harsh potential side effects of therapy, and in spite of the reality that the cancerous tumors might just keep coming back. Abiraterone Acetate is one of the interventions that have been considered in this regard because it causes a dramatic reduction in PSA levels and Tumor sizes, especially in aggressive advanced-stage prostate type of cancerfor most patients.

Chemotherapy is another approach that is hugely respected because it generally slows disease progression for hormonal refractory prostate cancer, and postpones its symptoms. Mostly, an oncologist would recommend the most commonly used regimen, which combines docetaxel with prednisone, a chemotherapeutic drug and a corticosteroid. Also as a compliment, bisphosphonates may be considered. Zoledronic acid, for instance, delays skeletal complications or the need for radiation therapy in patients with this aggressive late stage disease; while Alpharadin, a new alpha emitting pharmaceutical targets and controls bone metastasis.

As I write, zoledronic acid is still in research pending the realization of more impressive results from a randomized, placebo-controlled trial; and for how the amplification and overexpression of the androgen receptor gene might affect such a patient. Hey, the doctors and research specialists aren’t giving up so easily, even though they might not yet have the perfect cure for prostate cancer.

The truth is that one never knows if or how well a cancer of the prostatetreatment might work, regardless of the degree of metastasis of the disease. There are times when miracles do happen, and rather than giving up on yourself, you should look forward to the treatment with hope. You never know; you might just beat the malignancy into remission.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)


  1. Chemotherapy Prostrate Cancer

Speak Your Mind

Tell us what you're thinking... !

s